Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-11-29
2005-11-29
Park, Hankyel T. (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S005000, C435S325000, C435S320100, C536S023100
Reexamination Certificate
active
06969598
ABSTRACT:
A method for producing viral vectors is described using packaging and producer cell lines is described. The producer cell comprises: (i) a first nucleotide sequence (NS) encoding a toxic viral envelope protein operably linked to a promoter; wherein the promoter is operably linked to at least one copy of a TRE; (ii) a second NS wherein the second NS comprises a sequence encoding a tetracycline modulator; (iii) a third NS encoding a retrovirus nucleocapsid protein; and (iv) a fourth NS comprising a retroviral sequence capable of being encapsidated in the nucleocapsid protein such that the retroviral vector particle titre obtainable from the producer cell is regulatable by tetracycline and an initial stimulus with sodium butyrate or functional analogues thereof.
REFERENCES:
patent: 0 445 625 (1991-02-01), None
patent: WO 91/00047 (1991-01-01), None
patent: WO 92/05266 (1992-04-01), None
patent: WO 94/29438 (1994-12-01), None
patent: WO 94/29440 (1994-12-01), None
patent: WO 95/21927 (1995-08-01), None
patent: WO 95/30018 (1995-11-01), None
patent: WO 96/09400 (1996-03-01), None
patent: WO 96/35454 (1996-11-01), None
patent: WO 97/17457 (1997-05-01), None
patent: WO 97/27310 (1997-07-01), None
patent: WO 97/38117 (1997-10-01), None
patent: WO 98/05635 (1998-02-01), None
patent: WO 98/05754 (1998-02-01), None
patent: WO 98/05759 (1998-02-01), None
patent: WO 98/07859 (1998-02-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 98/17815 (1998-04-01), None
patent: WO 98/51810 (1998-11-01), None
patent: WO 99/15683 (1999-04-01), None
patent: WO 99/32646 (1999-07-01), None
patent: WO 99/41397 (1999-08-01), None
patent: WO 99/58155 (1999-11-01), None
patent: WO 99/61639 (1999-12-01), None
patent: WO 00/29428 (2000-05-01), None
patent: WO 00/31200 (2000-06-01), None
patent: WO 00/52188 (2000-09-01), None
patent: WO 01/25466 (2001-04-01), None
patent: WO 01/79518 (2001-10-01), None
Abe et al., “In Vitro Cell-Free Conversion of Noninfectious Moloney Retrovirus Particles to an Infectious Form by the Addition of the Vesicular Stomatitis Virus Surrogate Envelope G Protein,”Journal of Virology,72(8):6356-6361, Aug. 1998, American Society for Microbiology.
Akkina et al., “High-Efficiency Gene Transfer into CD34+Cells with a Human Immunodeficiency Virus Type 1-Based Retroviral Vector Pseudotyped with Vesicular Stomatitis Virus Envelope Glycoprotein G,”Journal of Virology,70(4):2581-2585, Apr. 1996, American Society for Microbiology.
Arai et al., “A New System for Stringent, High-Titer Vesicular Stomatitis Virus G Protein-Pseudotyped Retrovirus Vector Induction by Introduction of Cre Recombinase into Stable Prepacking Cell Lines,”Journal of Virology,72(2):1115-1121, Feb. 1998, American Society for Microbiology.
Attenello & Lee, “Regulation of a Hybrid Gene by Glucose and Temperature in Hamster Fibroblasts,”Science,226:187-190, Oct. 1984.
Benmansour et al., “Antigenicity of Rabies Virus Glycoprotein,”Journal of Virology,65(8):4198-4203, Aug. 1991, American Society for Microbiology.
Binns et al., “Companion of a Conserved Region in Fowlpox Virus and Vaccinia Virus Genomes and the Translocation of the Fowlpox Virus Thymidine Kinase Gene,”J. gen. Virol.,69:1275-1283, 1988, SGM, Great Britain.
Borrelli et al., “Targeting of an inducible toxic phenotype in animal cells,”Proc. Natl. Acad. Sci. USA,85:7572-7576, Oct. 1988.
Boyle et al., “Fowlpox Virus Thymideine Kinase: Nucleotide Sequence and Relationships to Other Thymidine Kinases,”Virology,156:355-365, 1987, Academic Press, Inc.
Burger et al., “Stable expression of rabies virus glycoprotein in Chinese hamster ovary cells,”Journal of General Virology,72:359-367, 1991, SGM, Great Britain.
Burns et al., “Vesicular stomatitis virus G glycoprotein pseudotypes retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,”Proc. Natl. Acad. Sci. USA,90:8033-8037, Sep. 1993.
Chen et al., “Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system,”Proc. Natl. Acad. Sci. USA,93:10057-10062, Sep. 1996.
Chen et al., “Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of a Liver Cytochrome P450 Gene,”Cancer Research,56:1331-1340, 1996.
Chung et al., “A 5′ Element of the Chicken β-Globin Domain Serves as an Insulator in Human Erythroid Cells and Protects against Effect in Drosophila,”Cell,74:505-514, Aug. 1993, Cell Press.
Coffin et al., “Retroviruses,” p. 449, JM Coffin et al., eds., Cold Spring Harbour Laboratory Press, 1997.
Coffin et al., “Retroviruses,” pp. 758-763, JM Coffin et al., eds., Cold Spring Harbor Laboratory Press, 1997.
Coll, “Synthetic peptides from the heptad repeats of the glycoproteins of rabies, vesicular stomatitis and fish rhabdoviruses bind phosphatidylserine,”Archives of Virology,142:2089-2097, 1997, Springer-Verlag, Austria.
Coll, “The glycoprotein G of rhabdoviruses,”Archives of Virology,140:827-851, 1995, Springer-Verlag, Austria.
Cosset et al., “High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum,”Journal of Virology,69(12):7430-7436, Dec. 1995, American Society for Microbiology.
Cosson, “Direct interaction between the envelope and matrix proteins of HIV-1,”The EMBO Journal,15(21):5783-5788, 1996, Oxford University Press.
Coulon et al., “An Avirulent Mutant of Rabies Virus Is Unable to Infect Motoneurons In Vivo and In Vitro,”Journal of Virology,72(3):273-278, Jan. 1998, American Society for Microbiology.
Coulon et al., “Invasion of the Peripheral Nervous Systems of Adult Mice by the CVS Strain of Rabies Virus and Its Avirulent Derivative AvO1,”Journal of Virology,63(8):3550-3554, Aug. 1989, American Society for Microbiology.
Dachs et al., “Targeting gene expression to hypoxic tumor cells,”Nature Medicine,3(5):515-520, May 1997.
Dietzschold et al., “Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus,”Proc. Natl. Acad. Sci. USA,80:70-74, Jan. 1983.
Dietzschold et al., “Isolation and Purification of a Polymeric Form of the Glycoprotein of Rabies Virus,”J. gen. Virol.,40:131-139, Great Britain.
Dietzschold et al., “Structure and Function of Rabies Virus Glycoprotein,”Develop. Biol. Standard,40:45-55, 1978, S. Karger, Basel.
Dietzschold, “Oligosaccharides of the Glycoprotein of Rabies Virus,”Journal of Virology,23(2):286-293, Aug. 1977, American Society for Microbiology, USA.
Dorfman et al., “Role of the Matrix Protein in the Virion Association of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein,”Journal of Virology,63(3):1689-1696, Mar. 1994, American Society for Microbiology.
Dougherty & Temin, “A promoterless retroviral vector indicates that there are sequences in U3 required for 3′ RNA processing,”Proc. Natl. Acad. Sci. USA,84:1197-1201, Mar. 1987.
Einfeld, “Maturation and Assembly of Retroviral Glycoproteins,” pp. 133-176.
Emerman & Temin, “Genes with Promoters in Retrovirus Vectors Can Be Independently Suppressed by an Epigenetic Mechanism,”Cell,39:459-467, Dec. 1984 (Part 2), MIT.
Emery et al., “A chromatin insulator protects retrovirus vectors from chromosomal position effects,”PNAS,97(16):9150-9155, Aug. 2000.
EMI et al., “Pseudotype Formation of Murine Leukemia Virus with the G Protein Vesicular Stomatitis Virus,”Journal of Virology,65(3):1202-1207, Mar. 1991, American Society for Microbiology.
Esposito & Knight, “Nucleotide Sequence of the Thymidine Kinase Gene Region of Monkeypox and Variola Viruses,”Virology,135:
Ellard Fiona Margaret
Kingsman Alan John
Mitrophanous Kyriacos Andreou
Olsen John C.
Rohll Jonathan
Oxford Biomedica (UK) Limited
Park Hankyel T.
The University of North Carolina at Chapel Hill
Townsend and Townsend / and Crew LLP
LandOfFree
Methods for producing high titre vectors and compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for producing high titre vectors and compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for producing high titre vectors and compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516887